Vista Capital Partners Inc. Has $145,000 Stock Position in Absci Co. (NASDAQ:ABSI)

Vista Capital Partners Inc. trimmed its stake in shares of Absci Co. (NASDAQ:ABSI) by 5.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 55,317 shares of the company’s stock after selling 3,000 shares during the quarter. Vista Capital Partners Inc.’s holdings in Absci were worth $145,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Rhumbline Advisers boosted its holdings in shares of Absci by 4.2% in the 4th quarter. Rhumbline Advisers now owns 114,152 shares of the company’s stock worth $299,000 after acquiring an additional 4,593 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Absci by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 49,379 shares of the company’s stock worth $189,000 after acquiring an additional 6,409 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in Absci by 5.9% during the 3rd quarter. Victory Capital Management Inc. now owns 150,562 shares of the company’s stock worth $575,000 after buying an additional 8,388 shares in the last quarter. PCA Investment Advisory Services Inc. acquired a new position in Absci during the 4th quarter worth $26,000. Finally, Alpha Cubed Investments LLC acquired a new position in Absci during the 4th quarter worth $26,000. 52.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Absci in a research report on Friday, January 17th. Needham & Company LLC initiated coverage on shares of Absci in a research report on Wednesday, January 22nd. They issued a “buy” rating and a $9.00 price objective for the company. KeyCorp lowered their price objective on shares of Absci from $6.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Finally, Guggenheim restated a “buy” rating and issued a $10.00 price objective on shares of Absci in a research report on Tuesday, December 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $8.57.

Absci Price Performance

ABSI stock opened at $5.79 on Wednesday. The stock has a 50-day moving average price of $3.65 and a two-hundred day moving average price of $3.73. The stock has a market cap of $665.04 million, a PE ratio of -6.23 and a beta of 2.11. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. Absci Co. has a 1 year low of $2.45 and a 1 year high of $6.72.

Absci Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.